Vivani Medical is a clinical-stage biopharmaceutical company developing miniature subdermal drug implants using proprietary NanoPortal™ technology to deliver medications over extended periods at near-constant rates, addressing chronic disease management and medication non-adherence. The company's pipeline includes implants for weight management and type 2 diabetes using GLP-1 receptor agonists, leveraging a biocompatible nanoporous membrane that enables long-acting, reversible drug delivery without moving parts. Vivani generates no current revenue while in development but intends to commercialize its technology either through partnerships with large pharmaceutical companies or by building internal sales capabilities in the substantial and growing global markets for obesity and diabetes treatments.